Preventing Loss of Independence Through Exercise (PLIÉ) - Pilot (PLIÉ-pilot)

June 2, 2015 updated by: Deborah Barnes, University of California, San Francisco

Maintaining Independence in Alzheimer's Disease

The primary goal of this study is to perform a 36-week pilot study with a cross-over design to study the safety and efficacy of a novel integrative exercise program called PLIÉ (Preventing Loss of Independence through Exercise). PLIÉ integrates elements of Eastern and Western exercise traditions and is specifically designed to target the muscles and movements needed to help individuals with mild-to-moderate dementia maintain physical function and independence.

Study Overview

Status

Completed

Conditions

Study Type

Interventional

Enrollment (Actual)

12

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • California
      • San Francisco, California, United States, 94118
        • Irene Swindells Center for Adult Day Services, Institute on Aging

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria - Primary Participant:

  • Current participant in the Irene Swindells Center for Adult Day Services in San Francisco, CA
  • Recommended by Swindells staff
  • mild-to-moderate dementia
  • caregiver consent

Inclusion Criteria - Caregiver:

  • Provide care to primary participant in the Irene Swindells Center for Adult Day Services in San Francisco, CA
  • can provide information about the primary participant's physical functioning, behaviors, falls, quality of life and own level of stress.

Exclusion Criteria - Primary Participant:

  • major current psychiatric illness (e.g., schizophrenia, bipolar disorder)
  • life expectancy < 1 year (e.g., metastatic cancer)
  • inability to assent to study procedures

Exclusion Criteria - Caregiver:

  • Any major neurologic disease (e.g., dementia, stroke, Parkinson's disease, ALS)
  • major current psychiatric illness (e.g., schizophrenia, bipolar disorder)
  • life expectancy < 1 year (e.g., metastatic cancer)
  • evidence of cognitive impairment
  • inability to consent to study procedures.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Group 1
PLIÉ exercise program 30-45 minutes, 2-3 days/week for 18 weeks followed by 18 weeks of usual care (20-minutes of chair-based exercises 2-5 days/week).
Integrative exercise program that incorporates elements of Eastern and Western exercise traditions to target the muscles and movements needed to help individuals with mild to moderate dementia maintain functional status and independence.
Active Comparator: Group 2
Usual care (20 minutes of chair-based exercises 2-5 days/week) for 18 weeks followed by the PLIÉ exercise program 30-45 minutes/day, 2-3 days/week for 18 weeks.
Integrative exercise program that incorporates elements of Eastern and Western exercise traditions to target the muscles and movements needed to help individuals with mild to moderate dementia maintain functional status and independence.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in physical function (participant)
Time Frame: Baseline, 18 weeks, 36 weeks
Participant's physical function will be assessed with the Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) scale (Galasko 1997). The ADCS-ADL is a 78-point scale that assesses functional ability in 23 daily activities based on informant report. It is the standard measure for assessment of functional status in AD treatment trials.
Baseline, 18 weeks, 36 weeks
Change in quality of life (participant)
Time Frame: Baseline, 18 weeks, 36 weeks
Quality of life will be assessed with the Quality of Life Scale in Alzheimer's Disease (QOL-AD), which is a brief, 13-item measure that obtains input from both the individual and the caregiver (Logsdon 1999). Scores may range from 13-52 points.
Baseline, 18 weeks, 36 weeks
Change in functional health and well-being (participant)
Time Frame: Baseline, 18 weeks, 36 weeks
Functional health and well-being will be assessed with the SF-36v2, which assesses function in eight domains and provides physical and mental component summary scores that may range from 0 to 70 (Stewart 1989). The SF-36v2 is typically administered directly to participants. However, we also will ask caregivers to answer questions on behalf of participants and will compare their answers to assess congruence. Data collected will help to determine if this measure is suitable for a larger trial.
Baseline, 18 weeks, 36 weeks
Change in number of falls (participant)
Time Frame: Baseline, 18 weeks, 36 weeks
Participant's falls will be assessed based on caregiver report.
Baseline, 18 weeks, 36 weeks
Change in fall-related self-efficacy (participant)
Time Frame: Baseline, 18 weeks, 36 weeks
Fall-related self-efficacy will be assessed with the Falls Efficacy Scale (FES), which is a 10-item scale that has been validated in individuals with cognitive impairment (Hauer 2010).
Baseline, 18 weeks, 36 weeks
Change in physical performance (participant)
Time Frame: Baseline, 18 weeks, 36 weeks
Physical performance will be assessed with the Short Physical Performance Battery (SPPB), which was developed by the National Institute on Aging to provide an objective tool for evaluating lower extremity functioning in older adults. The test includes repeated chair stands, tandem balance testing and 8' walking speed (Guralnik 1994).
Baseline, 18 weeks, 36 weeks
Change in cognitive function (participant)
Time Frame: Baseline, 18 weeks, 36 weeks
Cognitive function will be assessed with the Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog) (Rosen 1984), which is the most commonly used primary outcome measure in AD treatment trials. It is an 80-point scale that includes direct assessment of learning (word list), naming (objects), following commands, constructional Praxis (figure copying), ideational Praxis (mailing a letter), orientation (person, time, place), recognition memory and remembering test instructions.
Baseline, 18 weeks, 36 weeks
Compliance (participant)
Time Frame: Baseline, 18 weeks, 36 weeks
Participant compliance will be determined based on % of exercise classes attended from baseline to 18 weeks and from 18-36 weeks.
Baseline, 18 weeks, 36 weeks
Adverse events (participant)
Time Frame: Baseline, 18 weeks, 36 weeks
Number of adverse events from baseline to 18 weeks and from 18 weeks to 36 weeks will be monitored through biweekly telephone calls with caregivers.
Baseline, 18 weeks, 36 weeks
Change in dementia-related behaviors (participant)
Time Frame: Baseline, 18 weeks, 36 weeks
Participant's dementia-related behaviors will be assessed with the Neuropsychiatric Inventory (NPI), which is a 144-point informant-based questionnaire that assesses 12 behavioral domains common in dementia including frequency, severity and impact on caregiver distress (Cummings 1997).
Baseline, 18 weeks, 36 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in functional health and well-being (caregiver)
Time Frame: Baseline, 18 weeks, 36 weeks
Caregivers will be asked about the functional health and well-being of themselves as well as participants using the SF-36v2, which assesses function in eight domains and provides physical and mental component summary scores that may range from 0 to 70 (Stewart 1989).
Baseline, 18 weeks, 36 weeks
Change in burden (caregiver)
Time Frame: Baseline, 18 weeks, 36 weeks
Caregiver burden will be assessed with the Caregiver Burden Inventory (CBI), which is a 96-point scale that includes 24 items and 5 domains (Novak 1989).
Baseline, 18 weeks, 36 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Margaret Chesney, PhD, University of California, San Francisco
  • Principal Investigator: Deborah E Barnes, PhD, MPH, University of California, San Francisco

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2011

Primary Completion (Actual)

September 1, 2012

Study Completion (Actual)

September 1, 2012

Study Registration Dates

First Submitted

June 7, 2011

First Submitted That Met QC Criteria

June 8, 2011

First Posted (Estimate)

June 10, 2011

Study Record Updates

Last Update Posted (Estimate)

June 3, 2015

Last Update Submitted That Met QC Criteria

June 2, 2015

Last Verified

June 1, 2015

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Dementia

Clinical Trials on PLIÉ (Preventing Loss of Independence through Exercise)

Subscribe